bpc 157 subcutaneous vs intramuscular Where to Inject BPC-157: Site Guide What Is the GLOW

What Is the GLOW Blend? GHK-Cu + BPC-157 + TB-500

Clinical trial dosing: Phase IIa (METAOD005): 1, 5, 10, 20, or 30 mg/day oral administration for 12 weeks (n=300, 50 per dose group) Phase IIb (OPTIONS trial): 0.25, 0.5, or 1 mg/day oral administration for 24 weeks Community subcutaneous protocols: Starting dose: 300 mcg once daily Standard range: 300 to 500 mcg per day Some protocols escalate to 500 mcg split into two doses (250 mcg AM and 250 mcg before bed) if results plateau after 4 or more weeks Cycling: Standard cycle length: 12 weeks on, followed by 4 to 8 weeks off Some users run continuous protocols of up to 16 weeks before taking a break AOD-9604 should be administered in a fasted state, with a minimum of 2 hours since the last meal

Weight Loss

Volume:30ml

Use a consistent scale (0-10) for rating pain at rest and with activity